Natera (NTRA) announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA or ctDNA. This builds on Natera’s extensive intellectual property estate, including a strong portfolio of molecular residual disease testing ,MRD,patents for whole exome and whole genome sequencing. U.S. patent No. 12,203,142 relates to certain methods of preparation useful for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing. The patent describes various modes of target enrichment in the plasma, including both multiplex polymerase chain reaction PCR and capture by hybridization. Natera has more than 110 patents relating to cell-free DNA analysis for oncology testing, including 23 patents obtained in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $205 from $200 at Piper Sandler
- Natera’s Strong Market Position and Growth Potential Justify Buy Rating
- Natera Inc. Earnings Call Highlights Strong Growth and Future Prospects
- Natera price target raised to $188 from $183 at Baird
- Natera price target raised to $190 from $185 at BTIG